Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

Study entitled "Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced that its abstract, “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology”, has been published online in the Journal of Clinical Oncology, in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Pillar Biosciences will also be showcasing its highly accurate and sensitive NGS genetic testing technology at booth #17157 June 4 through June 6, 2022.

“There is a critical need for NGS tests that can accurately and rapidly identify somatic variants in cancer patients. Current NGS tests can have high failure rates which delay the return of actionable results to physicians, significantly impacting time to diagnosis and critical treatment decisions,” said Randy Pritchard, CEO of Pillar Biosciences. “The findings from our study underscore the accuracy and reliability of our SLIMamp® technology and demonstrate its ability to generate highly accurate results from lower quality samples that have failed other NGS tests. We are pleased that this study has been published online and look forward to demonstrating the capabilities of our NGS genetic testing solutions at ASCO.”

In the study, 48 tumor samples failing one or more pre-analytical quality control (QC) sample parameters for whole exome sequencing (WES) from an accredited diagnostic genomics laboratory were sequenced using Pillar Bioscience’s oncoRevealTM Solid Tumor Panel. Results demonstrated that the panel achieved high sequencing coverage (>3,000X) for all 48 samples and was able to generate clinical reports for 45 samples (94%). 38 of these reports (79%) contained clinically actionable or significant variants that would not have otherwise been identified with currently available panels. The study showed that oncoReveal™ Solid Tumor Panel with Pillar Biosciences’ proprietary SLIMamp® technology, was able to generate reliable, interpretable results for almost all of the samples that had failed pre-analytical QC for WES.

At booth #17157, Pillar Biosciences will also be featuring the company’s extensive portfolio of NGS genetic testing solutions, including the oncoReveal™ Dx Lung and Colon Cancer Assay, PillarHS Multi-Cancer Panel, Essential MPN Panel, Multi-Cancer with CNV and RNA Fusion Panel, and Myeloid Panel.

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions, including the FDA-approved oncoReveal™ Dx Lung and Colon Cancer Assay, are powered by the Company’s proprietary SLIMamp® and PiVAT® technologies, and decentralize the testing process, reducing diagnostic costs and improving access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The Company has more than 20 NGS testing products available in IVD or RUO formats, and several others in various stages of development, including a pan-cancer oncoReveal™ CDx assay, and two liquid biopsy offerings. Pillar’s patented technologies have been shown to provide accurate and actionable data in as little as 48 hours, which allows physicians to select appropriate therapies and monitor the patient’s response. Pillar Biosciences has operations in Natick, MA and Shanghai, China.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine